
UNDERSTANDING YOUR XIPERE® TREATMENT

How you can fight back against uveitic macular edema



Indication

XIPERE® (triamcinolone acetonide injectable suspension) is a corticosteroid used to treat macular edema associated with an eye disease called uveitis.

Important Safety Information

• Your eye doctor will monitor you for elevated eye pressure following treatment and manage it with medication or surgery if required.

Please see additional Important Safety Information throughout and full Prescribing Information <u>here</u>.



WHAT TO KNOW ABOUT UVEITIC MACULAR EDEMA

What is uveitic macular edema?

Uveitic macular edema is a complication of acute or chronic uveitis, or the inflammation of the uveal tract, and is the leading cause of visual impairment in cases with uveitis. Patients with this condition have an accumulation of fluid in the retinal layers or the subretinal space.

What are the symptoms?

Disturbance in contrast sensitivity

Your ability to distinguish between finer and finer increments of light versus dark

Difficulty reading

Metamorphopsia

Seeing straight lines as curved lines

Micropsia

Objects appearing smaller than they actually are

Positive relative scotoma

An area of vision loss presents itself as a black spot

How is it treated?

If it is not due to an infection, steroids likely will be used first and then other drugs may be used depending upon the response of the patient.

What happens if it goes untreated?

If macular edema continues for more than six months, cysts may form. Fibrosis and scarring from both edema and underlying uveitis may also occur. If that happens, the patient's visual outcome is usually poor.

DID YOU KNOW?

When a patient with uveitis experiences a decrease in vision, uveitic macular edema is the most frequent cause.

Important Safety Information (CONT)

• See your eye doctor right away if your eyes become red, sensitive to light or painful, or if you notice changes in vision.





WHAT IS XIPERE®?

A corticosteroid indicated for the treatment of macular edema associated with uveitis

How it works

A first-of-its-kind targeted therapy, XIPERE® is delivered through a space in the eye that has the potential to reach the back of your eye—which is where your macular edema associated with uveitis is happening.

This area is called the suprachoroidal space. XIPERE° is designed specifically to target this area, which surrounds the entire back part of your eye.

After your first XIPERE® injection

Your doctor will tailor a treatment regimen specific to your condition.




WHY XIPERE®?

In the treatment of uveitic macular edema, XIPERE® has been shown in clinical trials to provide a significant improvement in best corrected visual acuity (BCVA)

47%


Of patients in a clinical trial for XIPERE® achieved the improvement in BCVA (best corrected visual acuity) of ≥15 letters vs 16% of patients who were given a treatment that contained no medication.*

*XIPERE®, n=96; Control, n=64.



15 LETTERS GAINED

In clinical studies, XIPERE® provided a significant improvement in BCVA of ≥15 letters at 6 months from start of treatment in the group of patients on XIPERE® versus the no medication group.



WHAT'S BCVA?

You've heard of 20/20 vision, that's a reading of BCVA. If you have your vision corrected with glasses or contacts, it's the best you can see on the eye chart.

XIPERE® was well tolerated by patients in clinical trials

The safety of XIPERE was assessed across 3 studies that lasted as long as 48 weeks.



PREPARING FOR TREATMENT WITH XIPERE®



Check out this <u>playlist</u> to help you relax before your appointment on the ride over.



Have someone drive you to and from the office for your treatment as you may not be able to drive after.



Your eye doctor will use anesthesia applied to the eyelid and surface of the eye to help manage pain or discomfort.

To find out if XIPERE° is right for you. Talk to your doctor.



Important Safety Information (CONT)

• XIPERE® is not appropriate for use in patients with eye infections. It should be used with caution in patients with a history of herpes simplex in the eye.

Please see additional Important Safety Information throughout and full Prescribing Information in the here.



AFTER TREATMENT WITH XIPERE®



This is a first-of-its-kind targeted therapy which is delivered through a space in the eye that has the potential to reach the back of the eye—where your macular edema associated with uveitis is happening.

After your XIPERE® injection, your eye doctor will monitor you for elevated eye pressure following treatment and manage it with medication or surgery if required.

See your eye doctor right away if your eyes become red, sensitive to light or painful, or if you notice changes in vision.

If being treated with XIPERE® for extended periods of time, you will be monitored for problems with the body's hormonal system, which controls the ability to respond to stress.

In clinical studies, the most common eye-related side effects were increased eye pressure and eye pain. Other side effects included cataract, floaters or flashes of light, injection site pain, burst blood vessels, reduced or blurred vision, dry eye, light sensitivity, redness, infection, swelling, watery eyes, eye or eyelid irritation, bumps on the eyelid, itchy eyes, and drooping eyelid.

The most common non-eye-related side effect was headache.

Let your doctor know if you are pregnant or plan to become pregnant as corticosteroids should be used during pregnancy or nursing only if the potential benefit justifies the potential risk to the fetus or nursing infant.

50%

MAINTAINED AN AVERAGE OF ABOUT 12 LETTERS OF BCVA FOR NINE MONTHS

*Study included 28 patients who received XIPERE°

Important Safety Information (CONT)

 XIPERE® is not appropriate for use in patients with a known allergy to triamcinolone acetonide or any other components of this product.

Please see additional Important Safety Information throughout and full Prescribing Information <u>here</u>.



Bausch + Lomb is committed to providing savings and reimbursement support for XIPERE®

XIPERE® Savings Program

For More Information Reach out to a XIPERE® Savings Program Representative

Call 866-272-8838.




Reimbursement support

- 1. After your doctor determines that XIPERE® is right for you, their office staff will work with a FOCUS ON ACCESS® (FOA) Representative to complete a Patient Information and Enrollment form for you. Your doctor will ask you to sign the patient authorization section of the form.
- 2. Within 24 hours, an FOA representative will contact your insurance company to determine your health insurance benefits and coverage for XIPERE°. They will also determine if you may be eligible to pay as little as a \$0 copay through the XIPERE° Savings Program.
- 5. Then, a FOA representative will call you to explain your insurance coverage and discuss cost support options such as the XIPERE® Savings program.
- 4. Once that is completed, you can then schedule your first XIPERE® treatment.
- **5.** After that, you can continue to utilize FOA for support as needed, in case your insurance changes.

For More Information Reach out to a XIPERE® Savings Program Representative

Call 866–272–8838





Some days my macular edema may still hold me back, but I can feel good knowing that, together, we are

FIGHTING BACK WITH XIPERE®



Indication

XIPERE® (triamcinolone acetonide injectable suspension) is a corticosteroid used to treat macular edema associated with an eye disease called uveitis.

Important Safety Information

- Your eye doctor will monitor you for elevated eye pressure following treatment and manage it with medication or surgery if required.
- · See your eye doctor right away if your eyes become red, sensitive to light or painful, or if you notice changes in vision.
- XIPERE is not appropriate for use in patients with eye infections. It should be used with caution in patients with a history of herpes simplex in the eye.
- XIPERE is not appropriate for use in patients with a known allergy to triamcinolone acetonide or any other components of this product.
- Use of corticosteroids such as XIPERE may produce cataracts, increased eye pressure and glaucoma, and may increase the likelihood of eye infections.
- Patients being treated with XIPERE for extended periods of time will be monitored for problems with the body's hormonal system, which controls the ability to respond to stress.
- In clinical studies, the most common eye-related side effects were increased eye pressure and eye pain. Other side effects
 included cataract, floaters or flashes of light, injection site pain, burst blood vessels, reduced or blurred vision, dry eye,
 light sensitivity, redness, infection, swelling, watery eyes, eye or eyelid irritation, bumps on the eyelid, itchy eyes, and
 drooping eyelid.
 - The most common non-eye-related side effect was headache.
- Corticosteroids should be used during pregnancy or nursing only if the potential benefit justifies the potential risk to the fetus or nursing infant. Talk to your eye doctor.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit <u>www.fda.gov/medwatch</u>.

Please see additional Important Safety Information throughout and full Prescribing Information here.

BAUSCH + LOMB

XIPERE® and SCS® are trademarks of Clearside Biomedical, Inc. used under license. Focus on Access™ is a trademark of Bausch & Lomb Incorporated or its affiliates. © 2024 Bausch + Lomb, XIP.0059.USA.22_v3

